SCOPE 2019

Oracle integrates Quorum IRB tech to smooth submission process

By Melissa Fassbender

- Last updated on GMT

(Image: Getty/shirnosov)
(Image: Getty/shirnosov)

Related tags: Irb, Oracle, goBalto, regulatory approval, Clinical trials, Clinical development, Clinical operations

The collaboration between Quorum Review IRB and Oracle goBalto removes the need to send IRB submission documents manually.

The collaboration enables Quorum to push approval documents into Oracle goBalto’s Activate, explained Scott Smith, director of marketing at Quorum Review IRB. 

goBalto’s flagship product, Activate, is a study startup document and activity workflow solution that helps sponsors and contract research organizations (CROs) eliminate what it calls the three evil “e’s”: email, Excel, and e-rooms, according to the company, which was acquired by Oracle last year​.

Through the new collaboration, study teams will benefit from “point-and-click package submission and seamless data transfers,” ​Smith told us.

The integration also will use alerts to prevent errors and premature submissions. “Without this benefit, errors and submissions omissions become a time waster,”​ added Smith.

Oracle Health Sciences General Manager Steve Rosenberg said in a statement, “Automation has become critical for reducing the costs and complexities of clinical trials and this new level of integration eliminates time-consuming processes and improves operational efficiencies by addressing an entrenched bottleneck in the initiation process.”

Related news

Show more

Related products

show more

RACE Act Prompts Pediatric Oncology Trials

RACE Act Prompts Pediatric Oncology Trials

PRA Health Sciences | 04-May-2020 | Technical / White Paper

Many providers prescribe drugs off-label to pediatric patients, even though there have been few pediatric trials for many of these drugs. In response,...

Global Clinical Trial Lab Services

Global Clinical Trial Lab Services

Q2 Solutions | 01-Apr-2020 | Product Presentation

As a leading global lab services partner, we provide operational excellence, scientific leadership and innovation through technology. We offer end-to-end...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 01-Mar-2020 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

Related suppliers

Follow us

Products

View more

Webinars